Valuation: Avacta Group Plc

Market Cap 328M 437M 384M 357M 616M 42.13B 626M 4.24B 1.66B 20.71B 1.64B 1.61B 71.61B P/E 2026 *
-10x
P/E 2027 * -10.3x
Enterprise Value 322M 430M 378M 351M 606M 41.41B 615M 4.17B 1.63B 20.36B 1.61B 1.58B 70.39B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.8%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Avacta Group Plc

1 day+1.45%
Current month-4.76%
1 month-7.89%
3 months-5.79%
6 months+28.44%
Current year+20.69%
1 week 67
Extreme 67
72
1 month 67
Extreme 67
78
Current year 48
Extreme 48
92
1 year 41.33
Extreme 41.33
92
3 years 26
Extreme 26
166.98
5 years 26
Extreme 26
187.98
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Tech/Sci/R&D Officer - 09/02/2026
Director TitleAgeSince
Director/Board Member 60 03/02/2020
Director/Board Member 71 17/08/2021
Director/Board Member 56 18/03/2022
Date Insider Type Main position Quantity % Market Cap.
02/09/24 Fiscal year

Chief Financial Officer

500,000 0.1393%
02/09/24 Free

Chief Executive Officer

3,600,000 1.0027%
02/09/24 Sell

Chief Financial Officer

500,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
+1.45%0.00%+47.68%-28.50% 437M
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -0.79%+1.15%+40.94%+147.62% 24.05B
Weighted average by Cap. -0.87%+2.09%+39.71%+133.20%

Financials

2026 *2027 *
Net sales - -
Net income -33.4M -44.57M -39.14M -36.4M -62.77M -4.29B -63.73M -432M -169M -2.11B -167M -164M -7.3B -32.74M -43.68M -38.36M -35.67M -61.51M -4.21B -62.46M -424M -166M -2.07B -164M -160M -7.15B
Net Debt -5.58M -7.44M -6.54M -6.08M -10.48M -717M -10.64M -72.18M -28.2M -352M -27.94M -27.33M -1.22B 21.72M 28.98M 25.45M 23.67M 40.81M 2.79B 41.43M 281M 110M 1.37B 109M 106M 4.74B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
24/07/26 GBX 70.00 +1.45% 472,830
23/07/26 GBX 69.00 +1.47% 1,015,227
22/07/26 GBX 68.00 +1.49% 456,435
21/07/26 GBX 67.00 -0.74% 685,200
20/07/26 GBX 67.50 -3.57% 882,425
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.7000GBP
Average target price
0.8167GBP
Spread / Average Target
+16.67%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVCT Stock